A plain language summary of the final analysis of the GRIFFIN study of daratumumab plus lenalidomide, bortezomib, and dexamethasone for people with newly diagnosed multiple myeloma.

Autor:	Voorhees PM; Levine Cancer Institute, Atrium Health Wake Forest University School of Medicine, Charlotte, NC, USA., Sborov DW; Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA., Laubach J; Dana-Farber/Partners CancerCare, Harvard Medical School, Boston, MA, USA., Kaufman JL; Winship Cancer Institute, Emory University, Atlanta, GA, USA., Reeves B; Department of Medicine, University of North Carolina Chapel Hill, Chapel Hill, NC, USA., Rodriguez C; Icahn School of Medicine at Mount Sinai, New York, NY, USA., Silbermann R; Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA., Costa LJ; University of Alabama at Birmingham Hospital, Birmingham, AL, USA., Anderson LD; Myeloma, Waldenstrom's & Amyloidosis Program, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX, USA., Nathwani N; Judy & Bernard Briskin Center for Multiple Myeloma Research, City of Hope Comprehensive Cancer Center, Duarte, CA, USA., Shah N; Department of Medicine, University of California San Francisco, San Francisco, CA, USA., Bumma N; Division of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA., Efebera YA; OhioHealth, Blood & Marrow Transplant, Columbus, OH, USA., Holstein SA; Division of Oncology & Hematology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, USA., Costello C; Moores Cancer Center, University of California San Diego, La Jolla, CA, USA., Jakubowiak A; University of Chicago Medical Center, Chicago, IL, USA., Wildes TM; Division of Oncology & Hematology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, USA., Orlowski RZ; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Shain KH; Department of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, FL, USA., Cowan AJ; Division of Medical Oncology, University of Washington, Seattle, WA, USA., Dinner S; Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, USA., Gries KS; Janssen Research & Development, LLC, Raritan, NJ, USA., Pei H; Janssen Research & Development, LLC, Titusville, NJ, USA., Cortoos A; Janssen Scientific Affairs, LLC, a Johnson & Johnson company, Horsham, PA, USA., Patel S; Janssen Scientific Affairs, LLC, a Johnson & Johnson company, Horsham, PA, USA., Lin TS; Janssen Scientific Affairs, LLC, a Johnson & Johnson company, Horsham, PA, USA., Usmani SZ; Memorial Sloan Kettering Cancer Center, New York, NY, USA., Richardson PG; Dana-Farber/Partners CancerCare, Harvard Medical School, Boston, MA, USA.
Jazyk:	angličtina
Zdroj:	Future oncology (London, England) [Future Oncol] 2024 Oct 25, pp. 1-25. Date of Electronic Publication: 2024 Oct 25.
DOI:	10.1080/14796694.2024.2408909
Abstrakt:	What Is This Summary About?: This summary describes the final analysis of the GRIFFIN study. In this study, participants were newly diagnosed with a type of blood and bone marrow cancer called multiple myeloma, had never received any treatment, and were able to undergo an autologous stem cell transplant. The GRIFFIN study looked at adding the drug daratumumab (D) to a combination of standard treatments called RVd (lenalidomide [R], bortezomib [V], and dexamethasone [d]) during the treatment phases induction and consolidation, followed by daratumumab and lenalidomide (D-R) maintenance. Participants also received an autologous stem cell transplant to further help reduce multiple myeloma. The GRIFFIN study looked at whether D-RVd followed by D-R maintenance was better at killing multiple myeloma cells compared with RVd on its own followed by R maintenance on its own, and if treatments were safe. This summary also describes results from 2 other GRIFFIN publications: one that looked at participants with certain multiple myeloma characteristics or demographic factors that are associated with worse outcomes, and another that looked at how treatments impacted the participants' quality of life. What Were the Results?: At the time of the final analysis of GRIFFIN, participants who were treated with D-RVd followed by D-R maintenance had very low (undetectable) levels of multiple myeloma cells and multiple myeloma markers (biological signs) and were more likely to be alive without the multiple myeloma getting worse or coming back compared with participants who received standard RVd treatment followed by R maintenance. There was also a pattern of similar benefits achieved by participants who were at risk for worse outcomes. Additionally, participants who received D-RVd treatment followed by D-R maintenance reported less pain, less fatigue (extreme tiredness), and greater improvements in their ability to conduct daily physical activities. While some side effects (unwanted or unexpected effects of treatment) were higher with D-RVd, side effects in both groups were as expected, and adding daratumumab did not reduce a participant's ability to handle treatment. What Do the Results of the Study Mean?: Results of the GRIFFIN study showed that D-RVd treatment followed by D-R maintenance was better at treating multiple myeloma than the standard treatment of RVd followed by R maintenance in adults with a new diagnosis of multiple myeloma who were able to receive an autologous stem cell transplant, with no unexpected side effects of treatment. Clinical Trial Registration: NCT02874742 (GRIFFIN) (ClinicalTrials.gov).
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu